BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32624541)

  • 1. [Novel therapies for pediatric acute myeloid leukemia: building future strategies through incorporation of treatment currently used in adults].
    Moritake H
    Rinsho Ketsueki; 2020; 61(6):665-672. PubMed ID: 32624541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review].
    Xu B; Xiao Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):633-636. PubMed ID: 30998183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials.
    Sasine JP; Schiller GJ
    Blood Rev; 2015 Jan; 29(1):1-9. PubMed ID: 25441922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
    Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
    Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The progress and current status of immunotherapy in acute myeloid leukemia.
    Yang D; Zhang X; Zhang X; Xu Y
    Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
    Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
    J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches.
    Tosic N; Marjanovic I; Lazic J
    Biochem Pharmacol; 2023 Sep; 215():115705. PubMed ID: 37532055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
    Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
    J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Acute Myeloid Leukemia.
    Lichtenegger FS; Krupka C; Köhnke T; Subklewe M
    Semin Hematol; 2015 Jul; 52(3):207-14. PubMed ID: 26111468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
    Mahalleh M; Shabani M; Rayzan E; Rezaei N
    Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will CAR T cell therapy have a role in AML? Promises and pitfalls.
    Cummins KD; Gill S
    Semin Hematol; 2019 Apr; 56(2):155-163. PubMed ID: 30926092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
    Bader P; Klingebiel T; Schaudt A; Theurer-Mainka U; Handgretinger R; Lang P; Niethammer D; Beck JF
    Leukemia; 1999 Dec; 13(12):2079-86. PubMed ID: 10602432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
    Guy DG; Uy GL
    Curr Hematol Malig Rep; 2018 Dec; 13(6):417-425. PubMed ID: 30280288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia in children: Current status and future directions.
    Taga T; Tomizawa D; Takahashi H; Adachi S
    Pediatr Int; 2016 Feb; 58(2):71-80. PubMed ID: 26645706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of T Cell Immunotherapy in Acute Myeloid Leukemia.
    Hao F; Sholy C; Wang C; Cao M; Kang X
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy as consolidation of remission in pediatric AML relapsing post-transplant.
    Vettenranta K; Hovi L; Saarinen-Pihkala UM
    Pediatr Transplant; 2003 Dec; 7(6):446-9. PubMed ID: 14870891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotherapy for pediatric acute myeloid leukemia.
    Bonifant CL; Velasquez MP; Gottschalk S
    Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.